PlainRecalls
LowClass IIITerminated

FDA Drug recall · Reported May 31, 2023

Fentanyl Buccal Tablets CII, 100mcg, packaged in cartons of 28 Buccal Tablets (4 tablets x 7 cards), Rx only, Distributed by: Mayne Pharma, Greenville, NC 27834, NDC 51862-634-28

Labeling: Incorrect or Missing Package Insert

Recall #
D-0766-2023
Affected scope
438
Initiated
April 27, 2023
Compiled from official public sources by the editorial team.
Verify with FDA Drug →
View my saved recalls

Teva Pharmaceuticals USA Inc recalled Fentanyl Buccal Tablets CII, 100mcg, packaged in cartons of 28 Buccal Tablets (4 tablets … - a low-severity action.

Fentanyl Buccal Tablets CII, 100mcg, packaged in cartons of 28 Buccal Tablets (4 tablets … was recalled by Teva Pharmaceuticals USA Inc in May 31, 2023. Reason: Labeling: Incorrect or Missing Package Insert. Check the official notice for the remedy. Verify recall #D-0766-2023 with the FDA Drug before acting.

The recall

Teva Pharmaceuticals USA Inc issued this low-severity FDA Drug recall-Labeling: Incorrect or Missing Package Insert.

Low
severity level
438 units
affected scope
Class III
classification
May 31, 2023
reported

Sourced from official FDA Drug enforcement records. Verify recall #D-0766-2023 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.

Recall Insight

This FDA Drug action (record #D-0766-2023) was formally reported on May 31, 2023, with the manufacturer initiating the action on April 27, 2023. It is classified under Low severity (Class III), with a current status of Terminated. Teva Pharmaceuticals USA Inc is listed as the recalling firm, operating out of Parsippany, NJ. Federal records list the affected scope as 438.

The documented reason for this recall is: Labeling: Incorrect or Missing Package Insert Distribution data in the federal record shows the product reached: US Nationwide. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.

Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.

Drugs & Medications recalls over time

Where this recall sits in its category - 14,287 drugs & medications recalls on record

-50005001,0001,5002,000 2006201220152018202120242026 263
Severity2487872426High severity (most serious)Moderate severityLow severity
Where this recall sits in the database

Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified low severity.

Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.

Severity

Low

Affected scope

438

Related Recalls

6

5 from same agency

Product description

Fentanyl Buccal Tablets CII, 100mcg, packaged in cartons of 28 Buccal Tablets (4 tablets x 7 cards), Rx only, Distributed by: Mayne Pharma, Greenville, NC 27834, NDC 51862-634-28

Reason for recall

Labeling: Incorrect or Missing Package Insert

Recall Profile

Structured summary of the FDA Drug recall record
Attribute Value
Agency U.S. Food and Drug Administration
Severity class Low (Class III)
Status Terminated
Recall number D-0766-2023
Date reported May 31, 2023
Date initiated April 27, 2023
Recalling firm Teva Pharmaceuticals USA Inc
Firm location Parsippany, NJ
Affected scope 438
Distribution US Nationwide

Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.

Scale of Impact

438 units affected - limited or regional distribution scale.

Regional (<10K units) ✓ This recall
Multi-state (10K – 100K units) -
Large-scale (100K – 1M units) -
Massive (≥1M units) -

Bracket cutoffs follow federal recall-disclosure conventions; bar widths scale linearly within each bracket. Source: PlainRecalls analysis of U.S. Food and Drug Administration filings.

What to do with this recall

Match your product against the recall record, then act on the agency remedy.

  • Check the recall number (D-0766-2023) and product description against the item you own. Search the archive
  • Confirm the current status with FDA Drug before acting, recall details can be updated.
  • Follow the documented remedy (refund, replacement, repair, or disposal) rather than general advice. What to do next

This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.

Frequently Asked Questions

What product was recalled?
Fentanyl Buccal Tablets CII, 100mcg, packaged in cartons of 28 Buccal Tablets (4 tablets x 7 cards), Rx only, Distributed by: Mayne Pharma, Greenville, NC 27834, NDC 51862-634-28. Recalled by Teva Pharmaceuticals USA Inc. Units affected: 438.
Why was this product recalled?
Labeling: Incorrect or Missing Package Insert
Which agency issued this recall?
This recall was issued by the FDA Drug on May 31, 2023. Severity: Low. Recall number: D-0766-2023.
Where was the recalled product distributed?
Distribution: US Nationwide.
How do I check if my product is affected by a recall?
Check the product description and recall number (D-0766-2023) against your product. Visit the official FDA Drug website for the most current information. You can also use our Recall Checker tool to search by product name or brand.
Should I stop using a recalled medication or medical device?
Do not stop using a recalled medication or device without consulting your healthcare provider first, as abruptly discontinuing treatment could pose its own health risks. Your doctor can advise on alternatives or whether the recall applies to your specific product lot. Check the recall number and lot information against your product packaging.

Nearby Recalls in This Category

Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.

Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →

Browse all Drugs & Medications recalls →

Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported May 31, 2023. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.